Can MS drug vumerity be safe during pregnancy? a global registry seeks answers

NCT ID NCT05658497

Recruiting now Knowledge-focused Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This registry study follows women with multiple sclerosis (MS) who become pregnant, comparing those who took the medication Vumerity (diroximel fumarate) with those who took other MS treatments or no treatment at all. The main goal is to estimate the risk of major birth defects in babies born to women exposed to Vumerity early in pregnancy. By tracking pregnancy outcomes, the study aims to provide better safety information for women with MS who are planning a family.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Diroximel fumarate (Vumerity), an oral medication for multiple sclerosis
What this could lead to: If successful, this registry could provide clearer safety data on using Vumerity during pregnancy, helping women with MS and their doctors make more informed treatment decisions.
What could go wrong: As an observational registry, it cannot prove cause and effect. Results may be influenced by underlying disease severity or other factors, and the study relies on voluntary reporting, which may introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Austin Hospital
RECRUITING

Heidelberg, 3084, Australia
Hospital Universitario Ramon y Cajal
RECRUITING

Madrid, 28034, Spain
IQVIA US Office
RECRUITING

Durham, North Carolina, 27703, United States
Inselspital
RECRUITING

Bern, 3010, Switzerland
Katholisches Klinikum Bochum
RECRUITING

Bochum, North Rhine-Westphalia, 44791, Germany
Salford Care Organization
RECRUITING

Salford, Greater Manchester, M68HD, United Kingdom
St Vincent's University Hospital
RECRUITING

Dublin, DO4 T6F4, Ireland
University of Colorado Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.